1 completed, 1 terminated. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Terminated 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Palbociclib 75mg: new trials by email Literature Review of Palbociclib 75mg trials Research Report on Palbociclib 75mg
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer Palbociclib 75mg, Letrozole 2.5mg, T-DM1 - HER2-positive Breast Cancer, Breast Cancer Metastatic | Phase 1 / Phase 2 | Terminated | University of Kansas Medical Center | 3 | 2018-10-15 | 2024-03-05 |
| A Study To Investigate Palbociclib (PD-0332991) Pharmacokinetics In Healthy Subjects Of Japanese Descent Relative To Healthy Non-Asian Subjects, And To Determine If Changes In Palbociclib Dose Result In Proportional Changes In Palbociclib Plasma Exposure In Japanese Subjects Palbociclib 75mg, Palbociclib 125mg, Palbociclib 100mg - Healthy | Phase 1 | Completed | Pfizer | 27 | 2014-03-01 | 2014-06-24 |
Pfizer (1) · University of Kansas Medical Center (1)
United States (2)
Lauren Nye, MD (1)